Arlene Feder, MD
Endocrinology, Diabetes & Metabolism · Weirton, WVNPI 1508867979
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 817 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,775 and has fallen 66.1% since, to $1,279 in 2025.
Across 817 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$2K
- Insulet Corporation$2K
- Amneal Pharmaceuticals LLC$2K
- Lilly USA, LLC$989
- Corcept Therapeutics$863
- plus $10K from 40 others
What the payments were for
- Speaking & faculty fees$4402%
- Food & beverage$18,92496%
- Education$1981%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$538
- iLet Bionic Pancreas$374
- V-GO$321
- SOLIQUA 100/33$307
- CeQur Simplicity$190
- AFREZZA$152
- TWIIST$150
- iLet Insulin Infusion Kit Inset$125
- iLet Insulin Infusion Kit Contact Detach$125
- INVOKANA$119
- TOUJEO$110
- TZIELD$102
- Wegovy$101
How this compares
$19,621 in reported general payments places this provider in the 85th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 76 | $93,288 |
| OzempicSemaglutide | 78 | $91,862 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 54 | $61,061 |
| KerendiaFinerenone | 52 | $56,760 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 35 | $37,882 |
| Teriparatide | 12 | $34,571 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $33,994 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $33,638 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 45 | $32,320 |
| FarxigaDapagliflozin Propanediol | 52 | $30,160 |
| JardianceEmpagliflozin | 46 | $29,328 |
| Humulin R U-500Insulin Regular, Human | 19 | $27,544 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 39 | $19,534 |
| LyumjevInsulin Lispro-Aabc | 16 | $17,205 |
| NovologInsulin Aspart | 52 | $16,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Xultophy 100-3.6, Fiasp | $2,534 | $131,990153 claims |
| Lilly USA, LLCMounjaro, Lyumjev, Insulin Lispro, Humalog | $989 | $120,885176 claims |
| BayerKerendia | $479 | $56,76052 claims |
| Alvogen IncTeriparatide | $24 | $34,57112 claims |
| AstraZenecaFarxiga | $506 | $30,16052 claims |
| Boehringer IngelheimJardiance | $627 | $29,32846 claims |
| MerckJanuvia | $110 | $13,23024 claims |
| Cequr CorporationCequr Simplicity | $248 | $11,81827 claims |
| AbbVieSynthroid | $759 | $7,068100 claims |
| Sanofi-aventis U.S. LLCLantus | $2,479 | $2,42413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $1,504 | $1,558201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Weirton
- Viorica CrisanWeirton$32
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
- Jeremy SouleBridgeport$109K
- Philip RyanMartinsburg$35K
- John EplingBridgeport$28K
- Greta GuyerSouth Charleston$22K
- Ziad KahwashSouth Charleston$17K
- Ayman ElkadryHuntington$13K
- Jessica PeriniMorgantown$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.